(Stockholm, is developing a drug candidate for the treatment of endometriosis): Has raised 26.5 MEUR in a funding round led by Innovestor Life Science, with participation from Hadean Ventures, Linc, Foreground Capital, Catalyze Capital, Stephen Industries, Amboy Street Ventures, and Industrifonden with member Peter Wolpert. The funding will support a Phase II clinical trial in Europe.

Gesynta Pharma raises 26.5 MEUR
by
Tags: